Clinical trials: Cisplatin-induced Ototoxicity, open to volunteers
Childhood Medulloblastoma
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain.
- Trial name
- NCT05382338
- Testing
- Audiometric Test, Auditory Brainstem Response, Biospecimen Collection
- Where
- 111 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- Children's Oncology Group
Head Cancer, Neck Cancer
Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study
The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy
- Trial name
- AURACCO (NCT05946577)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ototoxic Hearing Loss, Ototoxicity, Drug-Induced
Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer
The goal of this observational study is to learn about the occurrence of and to identify suitable strategies for screening and monitoring of inner ear damage in patients receiving cisplatin chemoradiotherapy for head and neck…
- Conditions
- Ototoxic Hearing Loss, Ototoxicity, Drug-Induced, Cisplatin-induced Hearing Loss, Cisplatin Ototoxicity
- Trial name
- NCT06929468
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Simon Jäger
Ototoxic Hearing Loss
Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy
One common side effect of cisplatin chemotherapy is ototoxicity. The drugs sodium thiosulfate and mannitol may protect against cisplatin-induced hearing loss.
- Trial name
- NCT05129748
- Testing
- Sodium Thiosulfate + Mannitol
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- Sunnybrook Health Sciences Centre
Head and Neck Cancer, Hearing Loss
Maximizing Quality of Life After Cancer Through Rehabilitation
Treatment for head and neck cancer (HNC) often includes cisplatin chemotherapy and radiation. This treatment causes hearing loss and trouble swallowing in 70% of patients.
- Conditions
- Head and Neck Cancer, Hearing Loss, Tinnitus, Dysphagia
- Trial name
- TIMELY REHAB (NCT07622407)
- Testing
- TIMELY REHAB
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- VA Office of Research and Development
Cancer, Hearing Loss Ototoxic
The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Hearing-Related Quality of Life
The study will assess the effect of cancer treatments on speech perception in noise, cognition, and hearing-related quality of life by monitoring 200 cancer patients receiving standard care for their underlying malignancy.
- Conditions
- Cancer, Hearing Loss Ototoxic, Cognitive Decline, Quality of Life
- Trial name
- CaSPiN (NCT06551857)
- Testing
- Chemotherapy, chemoradiation, radiation therapy
- Where
- Finland
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Mucositis, Nephrotoxicity
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients.
- Conditions
- Mucositis, Nephrotoxicity, Ototoxicity
- Trial name
- NCT03480971
- Testing
- Tempol
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Matrix Biomed, Inc.
Cisplatin-induced Ototoxicity, Sensorineural Hearing Loss
Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial
The purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy.
- Conditions
- Cisplatin-induced Ototoxicity, Sensorineural Hearing Loss, Ototoxicity, Ototoxicity, Drug-Induced
- Trial name
- NCT07364747
- Testing
- Acetyl cysteine, Normal Saline
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Siriraj Hospital